ISSN : 0975-9492


Open Access

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information:
verify here.


Title : A study on the pharmacological management of mineral bone disease in chronickidney diseasepatients inatertiary care hospital
Authors : Syed Irfan Ali Ahmed, S.P.SrinivasNayak, K.R.Madhuri, Dr. B.Jyothi, Dr. K.Umamaheshwar Rao, Dr. V.Kiranmayi, Dr. V.Siva Kumar
Keywords : calcium; calcium x phosphate; chronic kidney disease; mineral bone disease;phosphate
Issue Date : Nov 2018
Abstract :
Background: In patients with chronic kidney disease (CKD), along with progression of CKD, abnormalities of mineral and bone metabolism develop, which result in altered serum levels of minerals such as calcium and phosphorus, as well as abnormalities in parathyroid hormone (PTH) or vitamin D metabolism. Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) is a serious burden because of increased cardiovascular mortality thus making therapeutic improvements essential in CKD-MBD. The present study was aimed at evaluation of pharmacological management of CKD-MBD. Methods:A retrospective study including 180 patients divided into two groups of 90 each (diabetes mellitus and non-Diabetes) was performed in the Department of Nephrology, SVIMS, Tirupati. Patients who were on follow up for at least 3 years (2015-2017) were considered, serum parameters were measured at every six months with a total of 6 visits. First visit was taken as baseline and sixth visit as conclusion. Results:The disease incidence of CKD-MBD is more common in male patients i.e. 67.8%. Serum calcium levels were significantly increased and eGFR was significantly decreased in all patients with CKD at conclusion compared to baseline.Further, Serum calcium levels were significantly increased at conclusion in CKD patients without DM and eGFR was significantly decreased at conclusion compared to baseline in CKD patients with DM. The proportion of untreated patients is high for all the drugs except vitamin D analogues in both subgroups of CKD patients. Conclusion:Pharmacological intervention in CKD patients helps in the effective management of mineral bone disease by maintaining serum calcium, phosphate and calcium phosphorous product status.
Page(s) : 201-206
ISSN : 0975-9492
Source : Vol. 9, No.11